Close Menu

Breaking News

The firm will use the funding for working capital for the Cyto-Mine single-cell analysis platform, UK facility expansion, and a new US sales office and demo lab.

Last week, GenomeWeb readers were most interested in a study linking an HIV-protective variant to an increase in all-cause mortality.

 Bio-Techne announced this week that it has agreed to acquire all of the stock of B-MoGen Biotechnologies.

The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.

In almost 1,000 twin pregnancies with known outcomes, cell-free DNA screening of maternal blood correctly classified trisomy 21 cases 94 percent of the time.

Researchers from the Broad Institute and NIH characterized a CRISPR-associated transposase that can integrate DNA into unique sites in the E. coli genome.

Variantyx, a 2014 spinout from Tel Aviv University that is based in Framingham, Massachusetts, provides clinical genomic testing for screening and rare disease diagnostics.

Most individuals had at least one tissue, of the 29 studied, containing clonal mutations, some of which are typically found in cancer cells.

Akonni has received clearance for a molecular diagnostic instrument and a saliva-based pharmacogenomics test for warfarin metabolism.

Bratislava-based HighChem offers software that is used by pharmaceutical and metabolomics laboratories for analyzing complex data and identifying small molecules.

Two research groups analyzed ancient DNA samples from across the Arctic to tease out how populations in Siberia and North America are related to one another.

The mCODE team recently released standards for inputting genomic and other data into patient records to boost patient record transferability and trial participation.

The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.

Almac said that the assay will be used in a clinical study of repotrectinib (TPX-0005), an investigational, next-generation tyrosine kinase inhibitor.

The company sold 2.2 million shares at an average price of $22.73 per share under a $50 million at-the-market equity facility it filed in March 2019.

Researchers reconstructed eight Yersinia pestis genomes using a method called "SNPEvaluation" that demonstrated genetic diversification among samples. 

Biotage will provide systems and consumables from its analytical chemistry portfolio to be sold by Yingsheng under its own brand.

A draft bill provides for a major expansion of eligible material, a move the ACLU and AMP said threatens to reduce competition in genetic testing.

In patients with a range of rare diseases, RNA sequencing in blood had a 7.5 percent diagnostic rate and identified candidate genes in 16.7 percent of cases.

Cytobank provides a cloud- and machine learning-based software platform for multi-parametric single-cell data analysis, sharing, and archiving.

ERS Genomics was founded to provide access to foundational CRISPR-Cas9 IP held by Emmanuelle Charpentier for applications other than human disease treatment.

The company announced the collaborations this week in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.

Individual stocks in the GenomeWeb Index were mostly down in May, with 21 of the 30 stocks posting losses and nine stocks recording gains.

Pages

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.